- Home
- FORR vs KZIA Comparison
FORR vs KZIA Comparison
Compare FORR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | KZIA |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 186.7M |
| IPO Year | 1996 | 2002 |
Fundamental Metrics
Financial Performance| Metric | FORR | KZIA |
|---|---|---|
| Price | $12.29 | $7.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 88.9K | ★ 229.9K |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $4.86 |
| 52 Week High | $12.75 | $17.40 |
Technical Indicators
Market Signals| Indicator | FORR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 37.13 |
| Support Level | $10.96 | $6.72 |
| Resistance Level | $12.75 | $8.18 |
| Average True Range (ATR) | 0.42 | 0.68 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 82.49 | 40.26 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.